TODAY’S PATENT – HUMANIZED ANTI-IL-6ANTIBODIES

The said invention with the patent number US8173398B2 was registered in USPTO on May 8th, 2012.

This innovation revolves around the development of novel antibodies designed to target a protein called interleukin-6 (IL-6). These antibodies are categorized into three main types: chimeric, humanized, or CDR-grafted.

Chimeric antibodies contain portions from both human and non-human sources, while humanized antibodies are predominantly human-derived with only small regions from non-human sources. CDR-grafted antibodies have their complementarity-determining regions (CDRs) replaced with those from other antibodies, usually human, to improve their compatibility with the human immune system.

The innovation also includes the isolation of nucleic acids that encode these anti-IL-6 antibodies. These nucleic acids serve as the genetic blueprints for producing the antibodies in various biological systems. Additionally, the invention covers vectors, host cells, transgenic animals, or plants engineered to produce these antibodies, providing versatile platforms for antibody production.

By providing a diverse range of antibody formats and production methods, this innovation holds promise for the development of effective treatments and therapies for a wide range of IL-6-related disorders.